Letter by Shah Regarding Article, “Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Argatroban, a direct thrombin inhibitor, has been of interest in vaso-occlusive stroke. ARGIS (Argatroban in Stroke), a retrospective review of 960 patients; ARTSS (Argatroban Treatment Stroke Study-1); and now ARTSS-2 have demonstrated the safety and potential use of argatroban in acute stroke.1–3 To date argatroban has not demonstrated increased risk of cerebral hemorrhage in ischemic stroke.
The hypothesis for argatroban’s role in stroke is predicated on recanalization to restore flow to the ischemic penumbra. However, despite limitations, ARTSS-2 recanalization rates were not …